Customized mycophenolate dosing based on measuring inosine-monophosphate dehydrogenase activity significantly improves patients outcomes after renal transplantation

Transplantation

Volumn 90, Issue 12, 2010, Pages 1536-1541

  Raggi, Matthias C ^a   Siebert, Stephanie B ^a   Steimer, Werner ^a   Schuster, Tibor ^b   Stangl, Manfred J ^a   Abendroth, Dietmar K ^c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

EC MPS; IMPDH; Kidney transplantation; MPA; MPAG

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID; PHENOLIC GLUCURONIDE MYCOPHENOLIC ACID; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; KIDNEY TRANSPLANTATION; KINETICS; MIDDLE AGED; MYCOPHENOLIC ACID; PREDICTIVE VALUE OF TESTS; TABLETS; TACROLIMUS;

EID: 78650827018     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182000027     Document Type: Article

References (30)

1. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715.
2. Halloran P, Mathew T, Tomlanovich S, et al. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. Transplantation 1997; 63: 39.
3. Shaw LM, Korecka M, Venkataramanan R, et al. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 2003; 3: 534.
4. Winnicki W, Weigel G, Sunder-Plassmann G, et al. An inosine 5- monophosphate dehydrogenase 2 single-nucleotide polymorphism impairs the effect of mycophenolic acid. Pharmacogenomics J 2010; 10: 70.
5. Meier-Kriesche HU, Steffen B, Hochberg A, et al. Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 2003; 75: 1341.
6. Kiberd BA, Lawen J, Fraser AD, et al. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am J Transplant 2004; 4: 1079.
7. Le Meur, Büchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007; 7: 2496.
8. van Gelder T, Silva HT, de Fijter JW, et al. Renal transplant patients at high risk of acute rejection benefit from adequate exposure to mycophenolic acid. Transplantation 2010; 89: 595.
9. Bunnapradist S, Lentine KL, Burroughs TE, et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 2006; 82: 102.
10. Albrecht W, Storck M, Pfetsch E, et al. Development and application of a high-performance liquid chromatography-based assay for determination of the activity of inosine-5-monophosphate dehydrogenase in whole blood and isolated mononuclear cells. Ther Drug Monit 2000; 22: 283.
11. Storck M, Abendroth D, Albrecht W. IMPDH activity in whole blood and isolated blood cell fraction for monitoring CellCept-mediated immunosuppression. Transplant Proc 1999; 31: 1115.
12. Shaw LM, Korecka M, DeNofrio D, et al. Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. Clin Biochem 2001; 34: 17.
13. Muller H, Solari S, Zuniga C, et al. Therapeutic drug monitoring of mycophenolic acid in kidney transplant patients: A abbreviated sampling strategy. Transplant Proc 2007; 39: 596.
14. Van Gelder T, Shaw LM. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation 2005; 80(2 suppl): 244.
15. Van Gelder T. Mycophenolate mofetil: How to further improve using an already successful drug? Am J Transplant 2005; 5: 199.
16. Vethe NT, Bremer S, Rootwelt H, et al. Pharmacodynamics of mycophenolic acid in CD4- cells: A single-dose study of IMPDH and purine nucleotide responses in healthy individuals. Ther Drug Monit 2008; 30: 647.
17. Langman LJ, Nakakura H, Thliveris JA, et al. Pharmacodynamic monitoring of mycophenolic acid in rabbit heterotopic heart transplant model. Ther Drug Monit 1997; 19: 146.
18. Budde K, Glander P, Hambach P, et al. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant 2004; 4: 2045.
19. Sombogaard F, van Schaik RH, Mathot RA, et al. Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757TC polymorphism. Pharmacogenet Genomics 2009; 19: 626.
20. Chiarelli LR, Molinaro M, Libetta C, et al. Inosine monophosphate dehydrogenase variability in renal transplant patients on long term mycophenolate mofetil therapy. Br J Clin Pharmacol 2009; 69: 38.
21. Schefold JC, Zeden JP, Fotopoulou C, et al. Tryptophan catabolites in patients with chronic kidney disease: A possible link between chronic inflammation and uraemic symptoms. Nephrol Dial Transplant 2009; 24: 1901.
22. Shaw LM, Mick R, Nowak I, et al. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol 1998; 38: 268.
23. Halloran PF, Helms LM, Kung L, et al. The temporal profile of calcineurin inhibition by cyclosporine vivo. Transplantation 1999; 68: 1356.
24. Maiguma T, Yosida T, Otsubo K, et al. Evaluation of inosine-5- monophosphate dehydrogenase activity during maintenance therapy with tacrolimus. J Clin Pharm Therap 2010; 35: 79.
25. Glander P, Sommerer C, Arns W, et al. Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients. Clin J Am Soc Nephrol 2010; 5: 503.
26. Opelz G, Döhler B. Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. Transplantation 2008; 86: 371.
27. Budde K, Bauer S, Hambach P, et al. Pharmacokinetik and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant 2007; 7: 888.
28. Ceglarek U, Casetta B, Lembcke J, et al. Inclusion ofMPAand in a rapid multi-drug LC-tandem mass spectrometric method for simultaneous determination of immunosuppressants. Clin Chim Acta 2006; 373: 168.
29. Shipkova M, Schutz E, Armstrong VW, et al. Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit. Clin Chem 2000; 46: 365.
30. Ceglarek U, Lembcke J, Fiedler GM, et al. Rapid simultaneous quantification of immunosuppressants in transplant patients by turbulent flow chromatography combined with tandem mass spectrometry. Clin Chim Acta 2004; 346: 181.